Pitavastatin calcium
|
|
|
- CAS-Nr.
- 147526-32-7
- Englisch Name:
- Pitavastatin calcium
- Synonyma:
- Pitavastatin Calcium Hydrate;Pivastatin calcium;Pitavastatin Calciu;nk104;D01862;P-872441;nk104(acid);nisvastatin;NK-104 Calcium;ITAVASTATIN CA
- CBNumber:
- CB6375308
- Summenformel:
- C25H26CaFNO4
- Molgewicht:
- 463.56
- MOL-Datei:
- 147526-32-7.mol
|
Pitavastatin calcium Eigenschaften
- Schmelzpunkt:
- >138oC (dec.)
- alpha
- D20 +23.1° (c = 1.00 in acetonitrile/water)
- storage temp.
- 2-8°C
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
- Optische Rotation
- [α]/D +19 to +24°, c =1 in acetonitrile: water (1:1)
- Stabilität:
- Hygroscopic
- InChIKey
- ADXNRJCYUMOXPZ-MNGIKBOWNA-N
- SMILES
- C(/C1C(C2CC2)=NC2C=CC=CC=2C=1C1C=CC(F)=CC=1)=C\[C@@H](O)C[C@@H](O)CC(=O)O.[Ca] |&1:22,25,r|
- CAS Datenbank
- 147526-32-7(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| S-Sätze: |
24/25 |
|
|
| WGK Germany |
WGK 3 |
|
|
| HS Code |
29339900 |
|
|
| Speicherklasse |
11 - Combustible Solids |
|
|
| Hazard Classifications |
Repr. 2 |
|
|
| Toxizität |
LDLo orl-rat: 500 mg/kg OYYAA2 56,67,1998 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Achtung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
 |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P305+P351+P338,P337+P313P |
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P271 |
Nur im Freien oder in gut belüfteten Räumen verwenden. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
| P332+P313 |
Bei Hautreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
| P337+P313 |
Bei anhaltender Augenreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
| P501 |
Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Pitavastatin calcium Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Pitavastatin, launched for the treatment of hypercholesterolemia, belongs to
the family of second-generation statins, also referred to as superstatins due to their
improved efficacy as cholesterol lowering agents. Like other statins, pitavastatin
reduces plasma cholesterol levels by competitively inhibiting HMG-CoA reductase,
the rate-limiting enzyme of cholesterol biosynthesis in the liver. It is a more potent
inhibitor of HMG-CoA reductase than the previously marketed statins and has the
potential benefit of not undergoing significant metabolism by CYP3A4. Pitavastatin
is synthesized in a multi-step sequence, including the key step of introducing the
dihydroxyheptenoate side chain by cross-coupling of a 3-iodoquinoline intermediate
with an alkenylborane reagent. Unlike rosuvastatin, pitavastatin has a high oral bioavailability (～80%). Plasma protein binding is
also high for pitavastatin (＞95%), and regardless of the dosing, the highest tissue
levels are found in the liver, its target organ. After oral administration, the peak
plasma concentration is reached at ,0.8 h and the mean elimination half-life is
～11 h. Pitavastatin is only minimally metabolized, mainly by CYP2C8 and
CYP2C9, and the predominant route of elimination of the parent drug and its
metabolites is by means of bile excretion followed by elimination in the feces. In clinical studies, oral doses of 2–4 mg/day of pitavastatin produced dose-dependent
reduction in LDL-cholesterol levels by 40–48% from baseline in patients with
heterozygous familial hypercholesterolemia. In a 12-week double-blind comparative
study, pitavastatin (2 mg/day) was more effective than pravastatin (10 mg/day) in
reducing LDL-cholesterol levels (38 and 18%, respectively); however, both agents produced similar increases in HDL-cholesterol (～9%). The drug was well tolerated
and the adverse reactions were mild and transient.
Chemische Eigenschaften
White to Off-White Powder
Verwenden
Pitavastatin calcium (Livalo) is a novel member of the medication class of statins
Definition
ChEBI: The calcium salt of pitavastatin. Used for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.
Hazard
A poison by ingestion.
Sicherheitsprofil
A poison by ingestion.Experimental reproductive effects. When heated todecomposition it emits toxic vapors of NOx and Fí.
Pitavastatin calcium Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Pitavastatin calcium Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 538)Lieferanten
147526-32-7()Verwandte Suche:
- Pitavasttin Calcium
- Pitavastatin Calcium /NK-104
- (+)-Monocalciunbis{(3r,5s,6e)-7-[2-cyclopropyl-4-(4-fluorophenyl-3-quinolyl]-3,5-dihydroxy-6-heptenotate}
- Pitavastatin calciuM(Livalo)
- Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-3,5-dihydroxyhept-6-enoate
- (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid,calcium salt (2:1)
- NK-104 Calcium
- Pitavastatin CalciuM
DISCONTINUED
- Pitavastatin (calcium salt)
- monocalciumbis[(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-Fluorophenyl)-3-Quinolyl)-3,5-Dihydroxy-6-heptenoate](+)a- Phenethylamine Sal
- Pitavastatin Calcuim
- Pitavastatin calcium, >=98.5%
- Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-3,5-dihydroxyhept-6-enoat
- PITAVASTATIN CALCIUM 3S-5R ISOMER IMP
- 6-heptenoicacid,7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydro
- calciumsalt(2:1),(3r,5s,6e)-xy
- nk104
- nk104(acid)
- ITAVASTATIN CA
- ITAVASTATIN CALCIUM
- PITAVASTATIN CALCIUM
- ：(+)-monocalciumbis{(3r,5s,6e)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate}
- monocalciumbis[(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-Fluorophenyl)-3-Quinolyl)-3,5-Dihydroxy-6-heptenoate](+)α－ Phenethylamine Salt
- D01862
- PITAVASTATINCALCIUM(FORR&DONLY)
- (+)-Monocalciumbis{(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate}
- PITAVASTATINHEMICALCIUM
- monocalciumbis[(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-Fluorophenyl)-3-Quinolyl)-3,5-Dihydroxy-6-heptenoate](+)a- Phenethylamine Salt
- 147526-32-7 Pitavastatin Calcium
- (3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic Acid Calcium Salt
- (3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid hemicalcium salt
- Pitavastatin calcium API
- Pitavastatin hemicalcium salt
- nisvastatin
- P-872441
- Pitavastatin caL
- DataBase Referen
- 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)-
- PITAVASTATIN CALCIUM CAS NO 147526-32-7
- Pitavastatin calcium USP/EP/BP
- Pitavastatin CalciumQ: What is
Pitavastatin Calcium Q: What is the CAS Number of
Pitavastatin Calcium Q: What is the storage condition of
Pitavastatin Calcium Q: What are the applications of
Pitavastatin Calcium
- Pitavastatin D4 Calcium SaltQ: What is
Pitavastatin D4 Calcium Salt Q: What is the CAS Number of
Pitavastatin D4 Calcium Salt Q: What is the storage condition of
Pitavastatin D4 Calcium Salt Q: What are the applications of
Pitavastatin D4 Calcium Salt
- Pitavastatin calcium high purity
- Pitavastatin Impurity 11 CaH2
- Pitavastatin Calcium, HMG-CoA reductase inhibitor
- Pitavastatin calcium, 10 mM in DMSO
- PITAVASTATIN CALCIUM (NON-STERILE DRUG SUBSTANCE)
- (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-yl]-3,5-dihydroxyheptyl-6-eneacidcalcium
- Pitavastatin calcium (Standard)
- Pitavastatin Calciu
- Pivastatin calcium
- Pitavastatin Calcium Hydrate
- 147526-32-7
- C50H46F2N2O8Ca
- C50H48CaF2N2O8
- C50H46CaF2N2O8
- C50H46F2N2O8Ca2
- C25H23FNO42Ca
